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Structure Based Discovery of a Novel Inhibitor of OXA-1 β-lactamase*
β-lactam antibiotics, such as penicillin,
are among the most commonly prescribed
group of antibiotics. These antibiotics are
characterized by a four-membered β-lactam
ring in their molecular structure, and they
act by binding to transpeptidase enzymes
found exclusively in bacteria, also called
penicillin binding proteins (PBPs). Once
the β-lactam binds to this target, bacterial
cell wall biosynthesis is disrupted and the
bacteria lyse and die.
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Unfortunately, due to the heavy use of
these antibiotics, bacteria developed
mechanisms that can render β-lactams
inactive and lead to resistance. Antibiotic
resistance in humans and in animals poses
a serious public health threat and is a
growing health concern worldwide.
One mechanism for bacterial resistance to
β-lactam antibiotics is the production of
a β-lactamase enzyme that hydrolyzes the
β-lactam ring of the antibiotic, making
the antibiotic ineffective against its target,
the bacterial cell wall transpeptidase.
Currently, there are four recognized classes
of β-lactamases (A-D) classified by their
unique mechanism for destroying β-lactam
antibiotics. Classes A, C and D act by a
serine based mechanism for destruction
which involves a two-step acylation/
deacylation reaction. Despite their increasing
clinical importance, class D β-lactamases are
among the least understood. To date, about
250 known class D β-lactamases have been
identified. OXA-1 is a member of the noncarbapenem-hydrolyzing subgroup of the
class D β-lactamases and the first discovered.

have chosen a structure-based approach
using DOCK, a molecular docking
program. DOCK computationally predicts
binding conformations of a database
of small molecules within a target site
on the enzyme. The ZINC database of
commercially available compounds was
used in our docking calculations and
allowed for millions of small compounds
to be screened against the target OXA1 active site. Compounds were ranked
by favorable interaction energies, and
the top compounds in the list suggested
possibilities for potential inhibitors. In part,
interaction energies are calculated based on
the size and shape of the molecule, as well
as the non-covalent interactions between
the molecule and OXA-1 active site. The
top hits, or compounds most likely to
inhibit based on their docking score, were
experimentally tested.
Structure-based docking led to the
identification of several novel leads that
inhibit OXA-1 β-lactamase. So far, 13
compounds from the lead-like subset have
been ordered and tested experimentally
for inhibition of OXA-1. Of the 13
compounds tested, five inhibited OXA1 with a Ki < 1 mM. Optimization of
a novel series of OXA-1 inhibitors is
currently underway.
*This scholar and faculty mentor have
requested that only an abstract be
published.

β-lactamase inhibitors were created in an
effort to combat these resistance enzymes.
Due to the similarities in structures of
both the β-lactam antibiotic substrate
and the inhibitor, bacteria have rapidly
evolved to develop mechanisms to resist
the inhibitors as well. Unfortunately, the
common clinical β-lactamase inhibitors
do not often inhibit class D β-lactamases.
Therefore, the major goal to studying the
class D β-lactamase OXA-1 is to discover
a competitive inhibitor that does not have
a structure similar to β-lactam compounds
because bacteria would not be able to
quickly evolve to develop mechanisms to
resist these non-β-lactam molecules.
The discovery of a novel inhibitor for an
enzyme target is a challenging task. We
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